SCHEMBL2489309

SCHEMBL2489309

O=C1COC=CO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11752553 0.88
SCHEMBL3657848 0.73
SCHEMBL4576510 0.71
SCHEMBL2360832 0.65
SCHEMBL2360831 0.65
SCHEMBL19873 0.61
SCHEMBL7659872 0.61
Methane SCHEMBL15227989 0.59
Bromide SCHEMBL30480806 0.59
SCHEMBL30449161 0.59

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109354497-B Ho-doped transparent scandium oxide ceramic and preparation method thereof INST. OF CHEMICAL MATERIAL, CHINA ACADEMY OF ENGINEERING PHYSICS (CN) 2021-06-22 CN claimed
US-20200330654-A1 Degradable Removable Implant for the Sustained Release of An Active Compound JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) 2020-10-22 US claimed
US-20140296799-A1 Degradable Removable Implant for the Sustained Release of An Active Compound Janssen Sciences Ireland Unlimited Company (IE) 2014-10-02 US claimed
US-8784858-B2 Degradable removable implant for the sustained release of an active compound JANSSEN R&D IRELAND (IE) 2014-07-22 US claimed
US-20040043943-A1 Method for the management of incontinence ALZA CORPORATION 2004-03-04 US claimed
US-20040037881-A1 Method for the management of incontinence ALZA CORPORATION 2004-02-26 US claimed
US-6262115-B1 ADMITTING ORALLY INTO THE PATIENT A DOSAGE FORM OF OXYBUTYNIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALT, THAT IS ADMINISTERED ONCE-A-DAY AS SUSTAINED-RELEASE FORM FOR MANAGEMENT OF INCONTINENCE ALZA COPORATION 2001-07-17 US claimed
US-20010005728-A1 Method for the management of incontinence ALZA CORPORATION 2001-06-28 US claimed
US-20260000691-A1 COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT JENNINGS BARBARA BROOKE (US) 2026-01-01 US disclosed
US-12435055-B2 3-methylideneoxan-4-one compounds and substituted derivates thereof as inhibitors of telomerase NORTHWESTERN UNIVERSITY (US) 2025-10-07 US disclosed
US-20250241554-A1 Magnetic Marker for Surgical Localization ENDOMAGNETICS LTD (GB) 2025-07-31 US disclosed
US-12329766-B2 Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development JENNINGS BARBARA BROOKE (US) 2025-06-17 US disclosed
US-12252477-B2 Applications of known and novel cannabinoids BESSOR PHARMA, LLC (US) 2025-03-18 US disclosed
US-20250064548-A1 Marker Materials and Forms for Magnetic Marker Localization (MML) ENDOMAGNETICS LTD (GB) 2025-02-27 US disclosed
US-5998485-A DOSE DEPENDENT CEDARS-SINAI MEDICAL CENTER (US) 1999-12-07 US disclosed
EP-0724429-B1 COMPOSITION AND METHOD FOR DELIVERY OF DRUGS ADVANCED RES & TECH INST (US) 1999-07-07 EP disclosed
WO-1998057620-A2 INOSITOL FOR MODULATION OF IMMUNE RESPONSE CEDARS-SINAI MEDICAL CENTER (US) 1998-12-23 WO disclosed
EP-0724429-A1 COMPOSITION AND METHOD FOR DELIVERY OF DRUGS INDIANA UNIVERSITY FOUNDATION (US) 1996-08-07 EP disclosed
US-5171217-A Injecting drug carried on microparticles of biocompatible biodegradable polymer into vessel wall under directed pressure INDIANA UNIVERSITY FOUNDATION (US) 1992-12-15 US disclosed
WO-1992015282-A2 COMPOSITION AND METHOD FOR DELIVERY OF DRUGS INDIANA UNIVERSITY FOUNDATION (US) 1992-09-17 WO disclosed